25 XP   0   0   10

Merus BV
Buy, Hold or Sell?

Let's analyse Merus together

PenkeI guess you are interested in Merus BV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Merus BV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Merus BV

I send you an email if I find something interesting about Merus BV.

Quick analysis of Merus (30 sec.)










What can you expect buying and holding a share of Merus? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.07
Expected worth in 1 year
$7.93
How sure are you?
31.6%

+ What do you gain per year?

Total Gains per Share
$1.86
Return On Investment
4.2%

For what price can you sell your share?

Current Price per Share
$44.52
Expected price per share
$30.81 - $52.04
How sure are you?
50%

1. Valuation of Merus (5 min.)




Live pricePrice per Share (EOD)

$44.52

Intrinsic Value Per Share

$-23.47 - $-27.38

Total Value Per Share

$-17.40 - $-21.31

2. Growth of Merus (5 min.)




Is Merus growing?

Current yearPrevious yearGrowGrow %
How rich?$356.3m$292.4m$13.6m4.5%

How much money is Merus making?

Current yearPrevious yearGrowGrow %
Making money-$38.7m-$32.7m-$5.9m-15.3%
Net Profit Margin-370.4%-337.4%--

How much money comes from the company's main activities?

3. Financial Health of Merus (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#154 / 1007

Most Revenue
#287 / 1007

Most Profit
#870 / 1007

Most Efficient
#694 / 1007

What can you expect buying and holding a share of Merus? (5 min.)

Welcome investor! Merus's management wants to use your money to grow the business. In return you get a share of Merus.

What can you expect buying and holding a share of Merus?

First you should know what it really means to hold a share of Merus. And how you can make/lose money.

Speculation

The Price per Share of Merus is $44.52. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Merus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Merus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.07. Based on the TTM, the Book Value Change Per Share is $0.47 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Merus.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.02-2.3%-0.63-1.4%-0.56-1.3%-0.41-0.9%-0.32-0.7%
Usd Book Value Change Per Share-0.63-1.4%0.471.0%-0.29-0.7%0.210.5%0.160.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.63-1.4%0.471.0%-0.29-0.7%0.210.5%0.160.3%
Usd Price Per Share27.50-23.95-21.15-19.76-15.67-
Price to Earnings Ratio-6.71--10.56--23.34--18.00--23.51-
Price-to-Total Gains Ratio-43.57--7.80--24.26--26.31--31.41-
Price to Book Ratio4.53-4.75-4.22-6.54-8.53-
Price-to-Total Gains Ratio-43.57--7.80--24.26--26.31--31.41-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share44.52
Number of shares22
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.470.21
Usd Total Gains Per Share0.470.21
Gains per Quarter (22 shares)10.244.71
Gains per Year (22 shares)40.9718.84
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1041310199
20827203828
3012311305747
4016415407566
5020519509485
602462360113104
702872770132123
803283180151142
903693590170161
1004104000188180

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.037.00.02.6%1.038.00.02.6%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%7.012.01.035.0%12.021.05.031.6%13.021.05.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.038.00.0%0.00.039.00.0%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%7.012.01.035.0%12.021.05.031.6%13.021.05.033.3%

Fundamentals of Merus

About Merus BV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Fundamental data was last updated by Penke on 2024-05-03 00:55:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Merus BV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Merus earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Merus to the Biotechnology industry mean.
  • A Net Profit Margin of -672.9% means that $-6.73 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Merus BV:

  • The MRQ is -672.9%. The company is making a huge loss. -2
  • The TTM is -370.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-672.9%TTM-370.4%-302.5%
TTM-370.4%YOY-337.4%-33.0%
TTM-370.4%5Y-258.8%-111.6%
5Y-258.8%10Y-1,993.2%+1,734.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-672.9%-183.7%-489.2%
TTM-370.4%-209.9%-160.5%
YOY-337.4%-269.7%-67.7%
5Y-258.8%-414.0%+155.2%
10Y-1,993.2%-584.7%-1,408.5%
1.1.2. Return on Assets

Shows how efficient Merus is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Merus to the Biotechnology industry mean.
  • -13.1% Return on Assets means that Merus generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Merus BV:

  • The MRQ is -13.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.1%TTM-9.6%-3.5%
TTM-9.6%YOY-8.4%-1.2%
TTM-9.6%5Y-7.4%-2.2%
5Y-7.4%10Y-18.7%+11.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.1%-12.7%-0.4%
TTM-9.6%-12.2%+2.6%
YOY-8.4%-11.2%+2.8%
5Y-7.4%-13.4%+6.0%
10Y-18.7%-15.0%-3.7%
1.1.3. Return on Equity

Shows how efficient Merus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Merus to the Biotechnology industry mean.
  • -16.9% Return on Equity means Merus generated $-0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Merus BV:

  • The MRQ is -16.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -13.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.9%TTM-13.4%-3.5%
TTM-13.4%YOY-12.4%-1.0%
TTM-13.4%5Y-13.3%0.0%
5Y-13.3%10Y-19.9%+6.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.9%-16.3%-0.6%
TTM-13.4%-15.6%+2.2%
YOY-12.4%-13.9%+1.5%
5Y-13.3%-18.7%+5.4%
10Y-19.9%-19.6%-0.3%

1.2. Operating Efficiency of Merus BV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Merus is operating .

  • Measures how much profit Merus makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Merus to the Biotechnology industry mean.
  • An Operating Margin of -531.8% means the company generated $-5.32  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Merus BV:

  • The MRQ is -531.8%. The company is operating very inefficient. -2
  • The TTM is -334.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-531.8%TTM-334.3%-197.5%
TTM-334.3%YOY-428.2%+93.9%
TTM-334.3%5Y-282.4%-51.9%
5Y-282.4%10Y-1,881.0%+1,598.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-531.8%-321.1%-210.7%
TTM-334.3%-224.1%-110.2%
YOY-428.2%-282.8%-145.4%
5Y-282.4%-440.7%+158.3%
10Y-1,881.0%-567.1%-1,313.9%
1.2.2. Operating Ratio

Measures how efficient Merus is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 10.37 means that the operating costs are $10.37 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Merus BV:

  • The MRQ is 10.372. The company is inefficient in keeping operating costs low. -1
  • The TTM is 7.705. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ10.372TTM7.705+2.667
TTM7.705YOY7.515+0.189
TTM7.7055Y5.243+2.462
5Y5.24310Y39.468-34.225
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.3723.090+7.282
TTM7.7053.241+4.464
YOY7.5153.670+3.845
5Y5.2435.388-0.145
10Y39.4687.284+32.184

1.3. Liquidity of Merus BV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Merus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.34 means the company has $5.34 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Merus BV:

  • The MRQ is 5.338. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.843. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.338TTM4.843+0.496
TTM4.843YOY5.603-0.761
TTM4.8435Y5.557-0.714
5Y5.55710Y6.406-0.849
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3383.805+1.533
TTM4.8434.158+0.685
YOY5.6035.268+0.335
5Y5.5576.088-0.531
10Y6.4066.419-0.013
1.3.2. Quick Ratio

Measures if Merus is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Merus to the Biotechnology industry mean.
  • A Quick Ratio of 7.37 means the company can pay off $7.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Merus BV:

  • The MRQ is 7.371. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.868. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.371TTM6.868+0.504
TTM6.868YOY7.782-0.914
TTM6.8685Y7.080-0.212
5Y7.08010Y7.608-0.528
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.3713.424+3.947
TTM6.8683.935+2.933
YOY7.7825.274+2.508
5Y7.0806.062+1.018
10Y7.6086.401+1.207

1.4. Solvency of Merus BV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Merus assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Merus to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.22 means that Merus assets are financed with 22.3% credit (debt) and the remaining percentage (100% - 22.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Merus BV:

  • The MRQ is 0.223. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.268. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.223TTM0.268-0.045
TTM0.268YOY0.294-0.026
TTM0.2685Y0.418-0.150
5Y0.41810Y0.562-0.143
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2230.349-0.126
TTM0.2680.340-0.072
YOY0.2940.273+0.021
5Y0.4180.366+0.052
10Y0.5620.387+0.175
1.4.2. Debt to Equity Ratio

Measures if Merus is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Merus to the Biotechnology industry mean.
  • A Debt to Equity ratio of 28.7% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Merus BV:

  • The MRQ is 0.287. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.377. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.287TTM0.377-0.090
TTM0.377YOY0.420-0.043
TTM0.3775Y0.828-0.452
5Y0.82810Y0.958-0.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2870.395-0.108
TTM0.3770.411-0.034
YOY0.4200.341+0.079
5Y0.8280.444+0.384
10Y0.9580.477+0.481

2. Market Valuation of Merus BV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Merus generates.

  • Above 15 is considered overpriced but always compare Merus to the Biotechnology industry mean.
  • A PE ratio of -6.71 means the investor is paying $-6.71 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Merus BV:

  • The EOD is -10.859. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.708. Based on the earnings, the company is expensive. -2
  • The TTM is -10.557. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.859MRQ-6.708-4.151
MRQ-6.708TTM-10.557+3.850
TTM-10.557YOY-23.343+12.786
TTM-10.5575Y-17.997+7.440
5Y-17.99710Y-23.510+5.513
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.859-2.322-8.537
MRQ-6.708-2.585-4.123
TTM-10.557-2.760-7.797
YOY-23.343-3.945-19.398
5Y-17.997-6.409-11.588
10Y-23.510-6.543-16.967
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Merus BV:

  • The EOD is -18.763. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.590. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.010. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-18.763MRQ-11.590-7.173
MRQ-11.590TTM-10.010-1.580
TTM-10.010YOY-7.901-2.109
TTM-10.0105Y-9.910-0.100
5Y-9.91010Y-16.349+6.438
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-18.763-2.968-15.795
MRQ-11.590-3.349-8.241
TTM-10.010-3.622-6.388
YOY-7.901-5.358-2.543
5Y-9.910-8.300-1.610
10Y-16.349-8.933-7.416
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Merus is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.53 means the investor is paying $4.53 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Merus BV:

  • The EOD is 7.332. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.529. Based on the equity, the company is fair priced.
  • The TTM is 4.754. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD7.332MRQ4.529+2.803
MRQ4.529TTM4.754-0.224
TTM4.754YOY4.223+0.530
TTM4.7545Y6.545-1.791
5Y6.54510Y8.525-1.981
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.3322.007+5.325
MRQ4.5292.073+2.456
TTM4.7542.093+2.661
YOY4.2232.827+1.396
5Y6.5453.576+2.969
10Y8.5253.986+4.539
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Merus BV.

3.1. Institutions holding Merus BV

Institutions are holding 87.618% of the shares of Merus BV.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31COMMODORE CAPITAL LP8.094411.407347473733193017.2108
2023-09-30Deerfield Management Co6.61032.0142387693884500027.87
2023-12-31Federated Hermes Inc6.20170.2483363730975160926.046
2023-12-31Samlyn Capital, LLC5.81821.868434124101558924.7871
2023-09-30Bvf Inc4.69291.75012752420115000071.7665
2023-12-31RTW INVESTMENTS, LLC4.04711.0196237362537686118.8736
2023-12-31Wellington Management Company LLP3.42610.01032009403-725844-26.5367
2023-09-30BRAIDWELL LP3.24180190133735817523.2105
2023-12-31Boxer Capital LLC3.23952.6042190000000
2023-12-31Franklin Resources Inc3.21070.02421883091-8835-0.467
2023-09-30VR Adviser, LLC2.94324.2849172621400
2023-12-31Medicxi Ventures Management (Jersey) Ltd2.72814.8533160000000
2023-12-31BlackRock Inc2.4380.0011429893-36043-2.4587
2023-12-31Driehaus Capital Management LLC2.23530.4343131101317581815.4879
2023-12-31Balyasny Asset Management LLC2.10270.0637123323837287943.3399
2023-12-31Pictet Asset Manangement SA2.1020.0374123280812328080
2023-12-31venBio Select Advisor LLC1.51560.3376888888444444100
2023-12-31Rock Springs Capital Management LP1.48690.5904872069336414.0124
2023-12-31Goldman Sachs Group Inc1.31950.0019773888567911275.7157
2023-12-31FMR Inc1.24540.0015730453-44500-5.7423
Total 68.699341.552640292370+5969117+14.8%

3.2. Funds holding Merus BV

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Federated Hermes Kaufmann Small Cap Grow3.71031.423217610127010114.1711
2023-12-31Federated Hermes Kaufmann Small Cap A3.71031.423217610127010114.1711
2023-12-31Federated Hermes Kaufmann Growth2.42990.8036142512247012249.2274
2023-12-31Federated Hermes Kaufmann R2.42990.8036142512247012249.2274
2024-03-31Franklin Biotechnology Discv A(acc)USD1.6152.3889947180518005.7853
2024-02-29Fidelity Select Biotechnology1.55640.900191281540706280.4863
2023-12-31Pictet-Biotech P USD1.28741.314675508711852318.6192
2023-12-31HBM Healthcare Investments AG Ord1.15940.936668000000
2024-03-31Franklin Biotechnology Discovery A0.8522.3688499698361007.7869
2024-03-31Franklin Small Cap Growth Adv0.68580.611740220000
2024-03-31Franklin Small Cap Growth SMA0.68580.61174022004021842513650
2024-03-31Franklin US Small Cap Growth Equity0.68580.61174022008940028.5806
2024-03-31BlackRock Health Sciences Term Trust0.65550.874338447200
2023-12-31Pictet-Global Megatrend Sel I USD0.63610.0817373083193215.4616
2024-03-28iShares Biotechnology ETF0.55420.191832506500
2024-03-31BlackRock Health Sciences Opps Inv A0.53660.164431473700
2024-02-29Wellington Global Hlthcr Eq USD G Ac0.44820.4849262846-125260-32.2747
2024-02-29Heptagon Driehaus US Micro Cap Eq C$ Acc0.39811.3915233503-39375-14.4295
2023-11-30MEDICAL BioHealth EUR Acc0.3950.856723164500
2024-03-31Belfius Equities Cure C Cap0.36320.5031213000-105076-33.0349
Total 24.794918.745714542177+2335125+16.1%

3.3. Insider Transactions

Insiders are holding 7.474% of the shares of Merus BV.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-19Harry ShumanSELL11526.68
2023-12-15Peter B. SilvermanSELL2238625
2023-12-01Harry ShumanSELL57524.58
2023-06-01Harry ShumanSELL57521.48

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Merus BV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.6310.466-236%-0.295-53%0.214-395%0.155-507%
Book Value Per Share--6.0725.217+16%4.984+22%3.557+71%2.269+168%
Current Ratio--5.3384.843+10%5.603-5%5.557-4%6.406-17%
Debt To Asset Ratio--0.2230.268-17%0.294-24%0.418-47%0.562-60%
Debt To Equity Ratio--0.2870.377-24%0.420-32%0.828-65%0.958-70%
Dividend Per Share----0%-0%-0%-0%
Eps---1.025-0.627-39%-0.559-45%-0.412-60%-0.317-69%
Free Cash Flow Per Share---0.593-0.616+4%-0.671+13%-0.433-27%-0.298-50%
Free Cash Flow To Equity Per Share---0.6140.352-275%-0.421-32%0.153-502%0.077-895%
Gross Profit Margin--1.0101.003+1%1.000+1%1.001+1%1.000+1%
Intrinsic Value_10Y_max---27.377--------
Intrinsic Value_10Y_min---23.473--------
Intrinsic Value_1Y_max---2.162--------
Intrinsic Value_1Y_min---2.123--------
Intrinsic Value_3Y_max---6.939--------
Intrinsic Value_3Y_min---6.616--------
Intrinsic Value_5Y_max---12.250--------
Intrinsic Value_5Y_min---11.332--------
Market Cap2612771952.000+38%1613909000.0001405714739.000+15%1240949302.000+30%1159637632.200+39%919820021.263+75%
Net Profit Margin---6.729-3.704-45%-3.374-50%-2.588-62%-19.932+196%
Operating Margin---5.318-3.343-37%-4.282-19%-2.824-47%-18.810+254%
Operating Ratio--10.3727.705+35%7.515+38%5.243+98%39.468-74%
Pb Ratio7.332+38%4.5294.754-5%4.223+7%6.545-31%8.525-47%
Pe Ratio-10.859-62%-6.708-10.557+57%-23.343+248%-17.997+168%-23.510+251%
Price Per Share44.520+38%27.50023.953+15%21.145+30%19.760+39%15.673+75%
Price To Free Cash Flow Ratio-18.763-62%-11.590-10.010-14%-7.901-32%-9.910-14%-16.349+41%
Price To Total Gains Ratio-70.530-62%-43.566-7.802-82%-24.260-44%-26.315-40%-31.409-28%
Quick Ratio--7.3716.868+7%7.782-5%7.080+4%7.608-3%
Return On Assets---0.131-0.096-27%-0.084-36%-0.074-44%-0.187+42%
Return On Equity---0.169-0.134-21%-0.124-27%-0.133-21%-0.199+18%
Total Gains Per Share---0.6310.466-236%-0.295-53%0.214-395%0.155-507%
Usd Book Value--356343000.000306164750.000+16%292478500.000+22%208724408.744+71%133188806.296+168%
Usd Book Value Change Per Share---0.6310.466-236%-0.295-53%0.214-395%0.155-507%
Usd Book Value Per Share--6.0725.217+16%4.984+22%3.557+71%2.269+168%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.025-0.627-39%-0.559-45%-0.412-60%-0.317-69%
Usd Free Cash Flow---34812822.000-36169955.500+4%-39384500.000+13%-25432592.541-27%-17497657.294-50%
Usd Free Cash Flow Per Share---0.593-0.616+4%-0.671+13%-0.433-27%-0.298-50%
Usd Free Cash Flow To Equity Per Share---0.6140.352-275%-0.421-32%0.153-502%0.077-895%
Usd Market Cap2612771952.000+38%1613909000.0001405714739.000+15%1240949302.000+30%1159637632.200+39%919820021.263+75%
Usd Price Per Share44.520+38%27.50023.953+15%21.145+30%19.760+39%15.673+75%
Usd Profit---60153000.000-38734750.000-36%-32798500.000-45%-24398600.023-59%-18481330.421-69%
Usd Revenue--8939000.00010986750.000-19%10396500.000-14%9871852.247-9%6445643.754+39%
Usd Total Gains Per Share---0.6310.466-236%-0.295-53%0.214-395%0.155-507%
 EOD+5 -3MRQTTM+16 -18YOY+13 -215Y+12 -2210Y+16 -18

4.2. Fundamental Score

Let's check the fundamental score of Merus BV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.859
Price to Book Ratio (EOD)Between0-17.332
Net Profit Margin (MRQ)Greater than0-6.729
Operating Margin (MRQ)Greater than0-5.318
Quick Ratio (MRQ)Greater than17.371
Current Ratio (MRQ)Greater than15.338
Debt to Asset Ratio (MRQ)Less than10.223
Debt to Equity Ratio (MRQ)Less than10.287
Return on Equity (MRQ)Greater than0.15-0.169
Return on Assets (MRQ)Greater than0.05-0.131
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Merus BV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.713
Ma 20Greater thanMa 5044.091
Ma 50Greater thanMa 10044.960
Ma 100Greater thanMa 20040.371
OpenGreater thanClose45.250
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets458,494
Total Liabilities102,151
Total Stockholder Equity356,343
 As reported
Total Liabilities 102,151
Total Stockholder Equity+ 356,343
Total Assets = 458,494

Assets

Total Assets458,494
Total Current Assets368,814
Long-term Assets89,680
Total Current Assets
Cash And Cash Equivalents 205,046
Short-term Investments 150,130
Net Receivables 3,981
Other Current Assets 9,657
Total Current Assets  (as reported)368,814
Total Current Assets  (calculated)368,814
+/-0
Long-term Assets
Property Plant Equipment 23,497
Long Term Investments 57,312
Intangible Assets 1,800
Long-term Assets Other 2,872
Long-term Assets  (as reported)89,680
Long-term Assets  (calculated)85,481
+/- 4,199

Liabilities & Shareholders' Equity

Total Current Liabilities69,089
Long-term Liabilities33,062
Total Stockholder Equity356,343
Total Current Liabilities
Short-term Debt 1,674
Accounts payable 4,602
Other Current Liabilities 40,128
Total Current Liabilities  (as reported)69,089
Total Current Liabilities  (calculated)46,404
+/- 22,685
Long-term Liabilities
Capital Lease Obligations 12,162
Long-term Liabilities  (as reported)33,062
Long-term Liabilities  (calculated)12,162
+/- 20,900
Total Stockholder Equity
Common Stock5,883
Retained Earnings -753,061
Accumulated Other Comprehensive Income -22,533
Other Stockholders Equity 1,126,054
Total Stockholder Equity (as reported)356,343
Total Stockholder Equity (calculated)356,343
+/-0
Other
Capital Stock5,883
Cash and Short Term Investments 355,176
Common Stock Shares Outstanding 57,826
Current Deferred Revenue22,685
Liabilities and Stockholders Equity 458,494
Net Debt -192,884
Net Invested Capital 356,343
Net Working Capital 299,725
Property Plant and Equipment Gross 31,240
Short Long Term Debt Total 12,162



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-31
> Total Assets 
17,119
0
4,305
0
8,556
46,391
38,806
32,574
81,886
77,409
76,049
76,049
255,819
244,161
236,105
236,105
268,187
261,070
249,965
249,965
228,414
207,730
263,376
237,962
223,661
213,493
231,217
397,949
379,583
355,927
456,600
417,500
444,793
414,990
376,542
338,520
363,624
492,186
458,494
458,494492,186363,624338,520376,542414,990444,793417,500456,600355,927379,583397,949231,217213,493223,661237,962263,376207,730228,414249,965249,965261,070268,187236,105236,105244,161255,81976,04976,04977,40981,88632,57438,80646,3918,55604,305017,119
   > Total Current Assets 
11,478
0
3,271
0
7,710
45,563
37,736
31,493
80,743
76,273
74,797
74,797
254,092
242,448
225,705
225,705
246,134
235,426
223,786
223,786
201,051
182,434
247,368
225,451
211,404
201,316
217,993
386,124
366,994
319,722
424,179
379,733
398,825
368,199
306,443
258,164
283,125
404,832
368,814
368,814404,832283,125258,164306,443368,199398,825379,733424,179319,722366,994386,124217,993201,316211,404225,451247,368182,434201,051223,786223,786235,426246,134225,705225,705242,448254,09274,79774,79776,27380,74331,49337,73645,5637,71003,271011,478
       Cash And Cash Equivalents 
14,671
0
2,239
0
7,368
45,124
35,916
29,640
79,142
74,352
59,860
59,860
246,849
237,679
179,569
179,569
196,933
166,011
164,433
164,433
150,076
135,100
197,612
165,800
152,088
139,179
163,082
327,137
311,472
159,121
241,435
194,575
213,930
190,980
147,749
102,635
101,096
241,868
205,046
205,046241,868101,096102,635147,749190,980213,930194,575241,435159,121311,472327,137163,082139,179152,088165,800197,612135,100150,076164,433164,433166,011196,933179,569179,569237,679246,84959,86059,86074,35279,14229,64035,91645,1247,36802,239014,671
       Short-term Investments 
12,000
0
12,000
0
0
0
12,000
12,000
12,000
12,000
12,000
0
0
0
40,841
40,841
42,869
58,370
51,310
51,310
40,432
37,249
42,153
48,234
45,278
51,021
44,673
47,248
41,280
150,617
168,990
164,239
162,177
160,463
142,480
138,604
163,950
146,702
150,130
150,130146,702163,950138,604142,480160,463162,177164,239168,990150,61741,28047,24844,67351,02145,27848,23442,15337,24940,43251,31051,31058,37042,86940,84140,84100012,00012,00012,00012,00012,00000012,000012,000
       Net Receivables 
742
0
677
0
259
376
384
437
1,119
1,389
2,479
2,479
6,345
4,085
3,777
3,777
4,021
5,949
8,044
8,044
4,680
3,732
2,652
1,717
2,106
2,293
1,749
1,954
3,690
3,599
6,673
3,167
4,372
3,147
4,698
5,610
3,812
4,607
3,981
3,9814,6073,8125,6104,6983,1474,3723,1676,6733,5993,6901,9541,7492,2932,1061,7172,6523,7324,6808,0448,0445,9494,0213,7773,7774,0856,3452,4792,4791,3891,11943738437625906770742
       Inventory 
0
0
0
0
0
0
0
0
0
0
12,460
12,460
0
495
0
0
0
0
-3,183
-3,183
0
0
3,038
7,821
8,289
6,947
7,431
8,419
9,184
5,246
4,906
15,318
15,729
12,658
9,312
8,902
12,219
10,256
0
010,25612,2198,9029,31212,65815,72915,3184,9065,2469,1848,4197,4316,9478,2897,8213,03800-3,183-3,1830000495012,46012,4600000000000
   > Long-term Assets 
0
0
1,034
0
846
829
1,069
1,081
1,142
1,135
1,250
1,250
1,726
1,713
10,400
10,400
22,053
25,644
26,178
26,178
27,363
25,296
16,008
12,511
12,257
12,177
13,224
11,825
12,589
36,205
32,421
37,767
45,968
46,791
70,099
80,356
80,499
87,354
89,680
89,68087,35480,49980,35670,09946,79145,96837,76732,42136,20512,58911,82513,22412,17712,25712,51116,00825,29627,36326,17826,17825,64422,05310,40010,4001,7131,7261,2501,2501,1351,1421,0811,06982984601,03400
       Property Plant Equipment 
535
0
429
0
323
323
355
374
476
496
682
682
1,209
1,184
1,401
1,401
2,169
2,278
2,768
2,768
9,840
10,137
8,930
8,386
8,148
8,021
8,022
7,267
8,358
7,593
7,282
6,843
19,768
19,684
24,840
25,712
24,995
23,499
23,497
23,49723,49924,99525,71224,84019,68419,7686,8437,2827,5938,3587,2678,0228,0218,1488,3868,93010,1379,8402,7682,7682,2782,1691,4011,4011,1841,20968268249647637435532332304290535
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
57
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000570000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,060
19,385
19,378
19,407
19,437
15,444
14,007
11,607
2,009
0
0
0
0
0
0
23,489
20,297
25,466
20,694
21,476
36,457
46,103
46,501
57,259
57,312
57,31257,25946,50146,10336,45721,47620,69425,46620,29723,4890000002,00911,60714,00715,44419,43719,40719,37819,3857,06000000000000000
       Intangible Assets 
768
0
604
0
0
0
476
478
446
437
393
393
391
328
374
374
443
2,767
2,797
2,797
2,543
2,492
2,876
2,739
2,731
2,784
2,843
2,645
2,608
2,471
2,347
2,233
2,076
1,889
1,950
1,933
1,882
1,771
1,800
1,8001,7711,8821,9331,9501,8892,0762,2332,3472,4712,6082,6452,8432,7842,7312,7392,8762,4922,5432,7972,7972,7674433743743283913933934374464784760006040768
       Long-term Assets Other 
0
0
0
0
523
506
238
231
217
203
176
176
125
144
155
155
193
1,110
1,230
1,230
844
1,031
1,905
1,275
1,168
1,081
1,949
1,872
1,483
2,433
2,078
3,145
3,189
3,307
4,811
4,239
4,064
4,123
2,872
2,8724,1234,0644,2394,8113,3073,1893,1452,0782,4331,4831,8721,9491,0811,1681,2751,9051,0318441,2301,2301,1101931551551441251761762032172312385065230000
> Total Liabilities 
6,562
0
8,632
0
17,973
7,981
7,863
6,289
5,844
5,902
40,258
40,258
172,588
174,011
178,655
178,655
160,808
162,386
144,873
144,873
141,127
130,732
132,076
123,376
123,365
128,992
128,954
161,412
160,496
150,158
140,399
120,027
118,184
116,213
129,487
120,997
106,219
98,798
102,151
102,15198,798106,219120,997129,487116,213118,184120,027140,399150,158160,496161,412128,954128,992123,365123,376132,076130,732141,127144,873144,873162,386160,808178,655178,655174,011172,58840,25840,2585,9025,8446,2897,8637,98117,97308,63206,562
   > Total Current Liabilities 
5,433
0
7,094
0
8,242
6,870
6,905
5,390
5,070
5,231
8,155
8,155
19,682
19,135
22,460
22,460
38,577
44,443
33,142
33,142
33,828
32,455
36,787
35,567
38,315
45,431
46,746
52,955
64,407
71,533
71,898
61,523
60,263
64,150
78,926
75,087
65,849
64,318
69,089
69,08964,31865,84975,08778,92664,15060,26361,52371,89871,53364,40752,95546,74645,43138,31535,56736,78732,45533,82833,14233,14244,44338,57722,46022,46019,13519,6828,1558,1555,2315,0705,3906,9056,8708,24207,09405,433
       Short-term Debt 
986
0
203
0
187
188
183
189
186
187
176
176
5,461
6,303
9,838
9,838
12,140
15,457
293
293
1,628
1,631
1,380
1,393
1,451
1,536
1,432
1,130
1,597
1,506
1,494
1,491
1,331
1,868
1,684
1,588
1,610
1,607
1,674
1,6741,6071,6101,5881,6841,8681,3311,4911,4941,5061,5971,1301,4321,5361,4511,3931,3801,6311,62829329315,45712,1409,8389,8386,3035,46117617618718618918318818702030986
       Short Long Term Debt 
986
0
167
0
0
0
167
1,000
1,000
542
167
0
0
0
0
0
0
0
0
982
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000982000000001675421,0001,0001670001670986
       Accounts payable 
3,501
0
2,929
0
3,623
2,948
2,645
1,802
1,903
2,226
2,417
2,417
4,543
3,331
3,425
3,425
6,282
8,352
4,369
4,369
3,031
2,683
3,029
3,381
2,362
4,720
3,126
3,715
6,160
5,401
13,237
5,388
6,961
3,117
9,834
4,987
7,596
3,843
4,602
4,6023,8437,5964,9879,8343,1176,9615,38813,2375,4016,1603,7153,1264,7202,3623,3813,0292,6833,0314,3694,3698,3526,2823,4253,4253,3314,5432,4172,4172,2261,9031,8022,6452,9483,62302,92903,501
       Other Current Liabilities 
1,702
0
2,405
0
2,219
1,720
2,419
2,517
2,509
2,336
3,869
3,869
459
427
535
535
364
410
9,110
9,110
9,431
9,363
13,536
12,159
15,931
19,819
22,009
22,356
24,529
27,526
22,506
20,948
21,257
31,190
37,990
41,814
32,492
35,849
40,128
40,12835,84932,49241,81437,99031,19021,25720,94822,50627,52624,52922,35622,00919,81915,93112,15913,5369,3639,4319,1109,1104103645355354274593,8693,8692,3362,5092,5172,4191,7202,21902,40501,702
   > Long-term Liabilities 
0
0
1,538
0
9,731
1,111
958
899
774
671
32,103
32,103
152,906
154,876
156,195
156,195
122,231
117,944
111,731
111,731
107,300
98,277
95,289
87,809
85,050
83,561
82,208
108,457
96,089
78,625
68,501
58,504
57,921
52,063
50,561
45,910
40,370
34,480
33,062
33,06234,48040,37045,91050,56152,06357,92158,50468,50178,62596,089108,45782,20883,56185,05087,80995,28998,277107,300111,731111,731117,944122,231156,195156,195154,876152,90632,10332,1036717748999581,1119,73101,53800
       Other Liabilities 
0
0
742
0
0
0
424
382
308
251
31,873
144,989
152,526
155,816
156,521
134,993
123,042
117,505
112,038
107,354
94,371
89,824
91,417
84,325
81,931
80,825
79,687
106,060
92,891
75,978
66,244
56,630
45,630
40,790
38,771
0
29,202
0
0
0029,202038,77140,79045,63056,63066,24475,97892,891106,06079,68780,82581,93184,32591,41789,82494,371107,354112,038117,505123,042134,993156,521155,816152,526144,98931,87325130838242400074200
       Deferred Long Term Liability 
0
0
742
0
0
0
424
0
0
0
31,860
0
0
0
156,340
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000156,34000031,86000042400074200
> Total Stockholder Equity
10,557
0
-4,328
0
-9,417
38,410
30,943
26,285
76,041
71,506
35,790
35,790
83,231
70,150
57,450
57,450
107,379
98,683
105,092
105,092
87,286
76,998
131,300
114,586
100,296
84,501
102,263
236,537
219,087
205,769
316,201
297,473
326,609
298,777
247,055
217,523
257,405
393,388
356,343
356,343393,388257,405217,523247,055298,777326,609297,473316,201205,769219,087236,537102,26384,501100,296114,586131,30076,99887,286105,092105,09298,683107,37957,45057,45070,15083,23135,79035,79071,50676,04126,28530,94338,410-9,4170-4,328010,557
   Common Stock
332
0
343
0
451
872
847
879
1,611
1,624
1,523
1,523
1,997
2,051
2,098
2,098
2,355
2,377
2,404
2,404
2,393
2,305
2,918
2,931
2,935
2,938
3,211
3,940
3,959
3,976
4,481
4,489
4,711
4,750
4,751
4,754
5,099
5,874
5,883
5,8835,8745,0994,7544,7514,7504,7114,4894,4813,9763,9593,9403,2112,9382,9352,9312,9182,3052,3932,4042,4042,3772,3552,0982,0982,0511,9971,5231,5231,6241,61187984787245103430332
   Retained Earnings Total Equity000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-1,346
0
0
0
-1,334
0
0
0
-1,459
0
0
0
-607
0
0
0
-1,203
0
0
0
1,586
-1,521
680
5,094
9,071
-320
3,155
-2,236
-9,221
-15,269
-35,190
-54,665
-30,448
-26,206
-26,711
-37,433
-22,533
-22,533-37,433-26,711-26,206-30,448-54,665-35,190-15,269-9,221-2,2363,155-3209,0715,094680-1,5211,586000-1,203000-607000-1,459000-1,334000-1,34600
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
360,045
286,490
286,491
286,506
441,395
444,275
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000444,275441,395286,506286,491286,490360,045000000000000000000
   Treasury Stock000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
44,900
0
46,872
101,734
99,391
103,054
155,706
156,926
147,110
147,110
244,279
250,744
256,278
256,278
298,371
300,674
302,967
302,967
301,165
289,819
441,395
444,275
445,754
448,617
490,093
643,183
649,627
656,536
787,869
794,074
848,623
864,842
870,874
876,838
948,913
1,117,855
1,126,054
1,126,0541,117,855948,913876,838870,874864,842848,623794,074787,869656,536649,627643,183490,093448,617445,754444,275441,395289,819301,165302,967302,967300,674298,371256,278256,278250,744244,279147,110147,110156,926155,706103,05499,391101,73446,872044,90000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue43,947
Cost of Revenue-127,408
Gross Profit-83,461-83,461
 
Operating Income (+$)
Gross Profit-83,461
Operating Expense-197,954
Operating Income-156,547-281,415
 
Operating Expense (+$)
Research Development140,658
Selling General Administrative59,836
Selling And Marketing Expenses2,540
Operating Expense197,954203,034
 
Net Interest Income (+$)
Interest Income0
Interest Expense-14,510
Other Finance Cost-25,256
Net Interest Income10,746
 
Pretax Income (+$)
Operating Income-156,547
Net Interest Income10,746
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-151,747-161,347
EBIT - interestExpense = -171,057
-151,747
-140,429
Interest Expense14,510
Earnings Before Interest and Taxes (EBIT)-156,547-137,237
Earnings Before Interest and Taxes (EBITDA)-154,007
 
After tax Income (+$)
Income Before Tax-151,747
Tax Provision-2,542
Net Income From Continuing Ops-176,758-154,289
Net Income-154,939
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses200,494
Total Other Income/Expenses Net4,800-10,746
 

Technical Analysis of Merus
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Merus. The general trend of Merus is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Merus's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Merus BV.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 49.50 < 52.04.

The bearish price targets are: 39.27 > 35.78 > 30.81.

Tweet this
Merus BV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Merus BV. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Merus BV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Merus BV. The current macd is 0.81958274.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Merus price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Merus. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Merus price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Merus BV Daily Moving Average Convergence/Divergence (MACD) ChartMerus BV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Merus BV. The current adx is 24.39.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Merus shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Merus BV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Merus BV. The current sar is 49.41.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Merus BV Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Merus BV. The current rsi is 48.71. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Merus BV Daily Relative Strength Index (RSI) ChartMerus BV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Merus BV. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Merus price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Merus BV Daily Stochastic Oscillator ChartMerus BV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Merus BV. The current cci is 9.80104187.

Merus BV Daily Commodity Channel Index (CCI) ChartMerus BV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Merus BV. The current cmo is -9.56003119.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Merus BV Daily Chande Momentum Oscillator (CMO) ChartMerus BV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Merus BV. The current willr is -55.95456129.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Merus is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Merus BV Daily Williams %R ChartMerus BV Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Merus BV.

Merus BV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Merus BV. The current atr is 2.01735371.

Merus BV Daily Average True Range (ATR) ChartMerus BV Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Merus BV. The current obv is 23,415,309.

Merus BV Daily On-Balance Volume (OBV) ChartMerus BV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Merus BV. The current mfi is 72.62.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Merus BV Daily Money Flow Index (MFI) ChartMerus BV Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Merus BV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-02MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Merus BV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Merus BV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.713
Ma 20Greater thanMa 5044.091
Ma 50Greater thanMa 10044.960
Ma 100Greater thanMa 20040.371
OpenGreater thanClose45.250
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Merus with someone you think should read this too:
  • Are you bullish or bearish on Merus? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Merus? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Merus BV

I send you an email if I find something interesting about Merus BV.


Comments

How you think about this?

Leave a comment

Stay informed about Merus BV.

Receive notifications about Merus BV in your mailbox!